Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
(Thomson Reuters ONE) -
Novartis International AG /
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive
advanced non-small cell lung cancer (NSCLC)
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior
median progression-free survival (PFS) compared to SOC chemotherapy with
maintenance[1]
* Zykadia benefit was also seen in patients with brain metastases[1]
* Approximately 3-7% of all patients with NSCLC have an ALK gene
rearrangement[2]
Basel, June 29, 2017 - Novartis today announced the European Commission approved
expanding the use of Zykadia(®) (ceritinib) to include the first-line treatment
of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are
anaplastic lymphoma kinase (ALK)-positive. Approval follows a positive opinion
granted in May by the Committee for Medicinal Products for Human Use (CHMP), and
is applicable to all 28 European Union member states plus Iceland, Lichtenstein,
and Norway.
The first-line approval of Zykadia is based on results from an open-label,
randomized, multicenter, global, Phase III trial, ASCEND-4. The study met its
primary endpoint, demonstrating a 45% reduction in the risk of disease
progression in the Zykadia arm, compared to the chemotherapy arm (hazard ratio
[HR] = 0.55 [95% confidence interval (CI): 0.42, 0.73; one-sided p value
<0.0001])[1]. Patients treated with first-line Zykadia had a median progression-
free survival (PFS) of 16.6 months (95% CI: 12.6, 27.2), compared to 8.1 months
(95% CI: 5.8, 11.1) for patients treated with standard first-line pemetrexed-
platinum chemotherapy with pemetrexed maintenance[1].
Overall intracranial response rate (OIRR) in patients with measurable brain
metastases at baseline and at least one post-baseline assessment was 72.7% (95%
CI: 49.8, 89.3; n = 22) for patients treated with Zykadia, versus 27.3% (95% CI:
10.7, 50.2; n = 22) for patients treated with chemotherapy[1]. The whole body
overall response rate (ORR) was 72.5% (95% CI: 65.5, 78.7; n = 189) in patients
treated with Zykadia[1].
Further, patients without brain metastases at screening receiving Zykadia
experienced a median PFS of 26.3 months (95% CI: 15.4, 27.7), compared with 8.3
months (95% CI: 6.0, 13.7) among patients treated with chemotherapy (HR = 0.48
[95% CI: 0.33, 0.69])[1]. Among patients with brain metastases at screening, the
median PFS was 10.7 months (95% CI: 8.1, 16.4) in the Zykadia group, versus 6.7
months (95% CI: 4.1, 10.6) in the chemotherapy group (HR = 0.70 [95% CI:
0.44, 1.12])[1].
"Today's EC approval of Zykadia as a first-line treatment of ALK+ non-small cell
lung cancer is an important step forward for patients with this type of serious
disease," said Bruno Strigini, CEO, Novartis Oncology. "Our commitment to
innovation in lung cancer will continue and we look forward to providing
additional advancements for patients as the incidence of the disease grows
around the world."
In May, US Food and Drug Administration (FDA) approved the expanded use of
Zykadia to include the first-line treatment of patients with metastatic non-
small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase
(ALK)-positive, as detected by an FDA-approved test.
Novartis Commitment to Lung Cancer
Worldwide, lung cancer causes more deaths than colon, breast and prostate cancer
combined, and an estimated 1.8 million new cases of lung cancer are diagnosed
each year[3],[4].
Over the past decade, Novartis Oncology's research has supported the evolution
of treatment approaches for patients living with mutation-driven types of lung
cancer. The company continues its commitment to the global lung cancer community
through ongoing studies, as well as the exploration of investigational compounds
that target genomic biomarkers in NSCLC.
About ASCEND-4
ASCEND-4 is a Phase III randomized, open-label, multicenter, global clinical
trial to evaluate the safety and efficacy of Zykadia compared to standard
chemotherapy, including maintenance, in adult patients with Stage IIIB or IV
ALK-positive advanced NSCLC who received no prior therapy for their advanced
disease. Patients received Zykadia orally at 750 mg/daily or standard
pemetrexed-based platinum doublet chemotherapy (pemetrexed 500 mg/m2 plus
cisplatin 75 mg/m2 or carboplatin AUC 5-6) for four cycles followed by
pemetrexed maintenance.
Of 376 patients, 189 (59 with brain metastases) were randomized to Zykadia and
187 (62 with brain metastases) to chemotherapy[1]. Approximately 59.5% of
patients with measurable brain metastases at baseline did not have prior
radiation therapy, the current standard of treatment for baseline brain
metastases[1]. One hundred and five (105) patients out of the 145 patients
(72.4%) that discontinued treatment in the chemotherapy arm received subsequent
ALK inhibitor as first antineoplastic therapy. Of these patients 81 received
Zykadia[1].
The most common adverse reactions in ASCEND-4 (incidence >=25% all grades) were
diarrhea (85%), nausea (69%), vomiting (67%), fatigue (45%), abdominal pain
(40%), decreased appetite (34%) and cough (25%). Grade 3/4 adverse reactions
(incidence >=2%) were fatigue (7%), vomiting (5%), diarrhea (4.8%), abdominal
pain (3.7%), weight loss (3.7%), nausea (2.6%) and prolonged QT interval (2.6%).
The most common laboratory abnormalities in ASCEND-4 (incidence >=25% all
grades) were increased ALT/AST (91%/86%), increased GGT (84%), increased
alkaline phosphatase (81%), creatinine increase (77%), anemia (67%),
hyperglycemia (53%), decreased phosphate (38%), increased amylase (37%) and
neutropenia (27%). Grade 3/4 laboratory abnormalities (incidence >=2%) were
increased GGT (49%), ALT/AST (34%/21%), increased alkaline phosphatase (12%),
hyperglycemia (10%), increased amylase (8%), increase lipase (6%), creatinine
increase (4.2%), anemia (4.2%), decreased phosphate (3.7%) and neutropenia
(2.1%).
About Zykadia
Zykadia is an oral, selective inhibitor of anaplastic lymphoma kinase (ALK), a
gene that can fuse with others to form an abnormal "fusion protein" that
promotes the development and growth of certain tumors in cancers including non-
small cell lung cancer (NSCLC). Zykadia is currently approved in over 70
countries worldwide. Please visit https://www.novartisoncology.com/news/product-
portfolio/zykadia for additional information.
Zykadia Important Safety Information
Zykadia may cause stomach upset and intestinal problems in most patients,
including diarrhea, nausea, vomiting and stomach-area pain. These problems can
be severe. Zykadia may also cause severe liver injury, abnormal heartbeats
(slow, fast, or irregular), severe or life-threatening swelling (inflammation)
of the lungs that can lead to death, pancreatitis, and high levels of pancreatic
enzymes or glucose (sugar) in blood.
Zykadia may harm unborn babies. Women who are able to become pregnant must use a
highly effective method of birth control (contraception) during treatment with
Zykadia and up to 3 months after stopping Zykadia. Patients and their healthcare
provider should decide whether to take Zykadia or breastfeed, but should not do
both.
Some side effects can be serious and patients should call your healthcare
provider immediately if experiencing changes in your heartbeat (fast, slow, or
irregular), lightheadedness, fainting, dizziness, pain in the chest, cough,
difficult or painful breathing, wheezing, pain in chest when inhaling, fever,
yellow skin and eyes, nausea, loss of appetite, dark urine, and severe upper
stomach pain.
Before taking Zykadia, patients should tell their healthcare provider about all
medical conditions, including liver problems, diabetes or high blood sugar,
heart problems, including a condition called long QT syndrome, if they are
pregnant, if they think they may be pregnant, or if they plan to become
pregnant, are breastfeeding or plan to breastfeed. Patients should also tell
their healthcare provider about all medicines they take. Patients should not
drink grapefruit juice or eat grapefruit during treatment with Zykadia, as it
may make the amount of Zykadia in their blood increase to a harmful level.
Patients should have blood tests before starting treatment with Zykadia to check
their liver, pancreas, and the level of sugar in blood. While taking Zykadia,
blood tests to check the liver should be performed monthly, while pancreas and
the level of sugar in blood should be performed regularly.
The most common adverse reactions with an incidence of >=10% diarrhea, nausea,
vomiting, liver laboratory test abnormalities, fatigue, abdominal pain,
decreased appetite, weight decreased, constipation, blood creatinine increased,
rash, anemia, and esophageal disorder. Grade 3-4 adverse reactions with an
incidence of >=5% were liver laboratory test abnormalities, fatigue, vomiting,
hyperglycemia, nausea, diarrhea.
Please see full Prescribing Information for Zykadia.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "continuing," "must," "continue," "hope," "commitment,"
"continues," "ongoing," "exploration," "investigational," or similar terms, or
by express or implied discussions regarding potential new indications or
labeling for Zykadia, or regarding potential future revenues from Zykadia. You
should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Zykadia will be submitted or approved for any
additional indications or labeling in any market, or at any particular time. Nor
can there be any guarantee that Zykadia will be commercially successful in the
future. In particular, management's expectations regarding Zykadia could be
affected by, among other things, the uncertainties inherent in research and
development, including clinical trial results and additional analysis of
existing clinical data; regulatory actions or delays or government regulation
generally; the company's ability to obtain or maintain proprietary intellectual
property protection; general economic and industry conditions; global trends
toward health care cost containment, including ongoing pricing and reimbursement
pressures; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
118,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis and (at)NovartisCancer at
http://twitter.com/novartiscancer.
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Zykadia® (ceritinib) Summary of Product Characteristics.
[2] Lovly, C., L. Horn, W. Pao. 2016. Molecular Profiling of Lung Cancer. My
Cancer Genome. https://www.mycancergenome.org/content/disease/lung-cancer/.
(Updated March 28). Accessed March 22, 2017.
[3] World Health Organization. International Agency for Research on Cancer.
GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in
2012. Lung Cancer. Available at
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=lung. Accessed
March 22, 2017.
[4] Riess JW, Wakelee, HA. Metastatic Non-Small Cell Lung Cancer Management:
Novel Targets and Recent Clinical Advances. Clinical Advances in Hematology &
Oncology. 2012; 10: 226-224.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Kristen Klasey
Novartis Global Media Relations Novartis Oncology
+41 61 324 7999 (direct) +1 862 778 4763 (direct)
+41 79 593 4202 (mobile) +1 862 754 1732 (mobile)
eric.althoff(at)novartis.com kristen.klasey(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2116418/805411.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2017 - 07:15 Uhr
Sprache: Deutsch
News-ID 550391
Anzahl Zeichen: 15790
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 265 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
